



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/</u> <u>Verified</u>
MYCN FISH Result	Not Amplified			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
	f				11:34:00	11:34:00	10:39:54
MYCN/CEP2 FISH Ratio	1.0			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
					11:34:00	11:34:00	10:39:54
Average MYCN Signal Number per Cell	2.0			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
					11:34:00	11:34:00	10:39:54
Average CEP2 Signal Number per Cell	2.0			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
					11:34:00	11:34:00	10:39:54
MYCN FISH Reference Number	S18-123			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
					11:34:00	11:34:00	10:39:54
MYCN FISH Source	Tissue			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
					11:34:00	11:34:00	10:39:54
Total Cell Count	50			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
					11:34:00	11:34:00	10:39:54
Scoring Method	Manual			18-347-900145	13-Dec-18	13-Dec-18	14-Dec-18
					11:34:00	11:34:00	10:39:54

13-Dec-18 11:34:00 MYCN FISH Result:

This result has been reviewed and approved by Deepika Sirohi, M.D. Controls performed as expected.

13-Dec-18 11:34:00 MYCN FISH Result:  
 METHODOLOGY AND INTERPRETIVE DATA:

Fluorescence in situ hybridization (FISH) analysis for MYCN gene amplification was performed on a section from a paraffin embedded tissue block using differentially labeled fluorescent probes targeting the MYCN gene and the chromosome 2 centromere (CEP2) (Abbott Molecular). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin and eosin stained section. Controls performed appropriately.

MYCN amplification (MYCN/CEP2 ratio of 2.0 or greater) is considered a feature of high-risk disease and an indicator of poor prognosis in neuroblastoma. Amplification is also seen in SHH-activated and group 4 medulloblastomas with implications for prognosis and therapy response.

Reference:

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A, Eds. WHO Classification of Tumours of the Central Nervous System, Revised 4th Edition. Lyon, France: International Agency for Research on Cancer, 2016.

\* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

**ARUP** Laboratories  
500 Chipeta Way – Salt Lake City, UT 84108  
(800)522-2787 - [www.aruplab.com](http://www.aruplab.com)  
Julio C. Delgado, M.D. M.S., Director of Laboratories

\*\*\*Example Report\*\*\*

Patient Age/Gender: Unknown Female  
Printed: 14-Dec-18 10:44:38

---

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: [aruplab.com/CS](http://aruplab.com/CS).

\* Abnormal, # = Corrected, **C** = Critical, **f** = Footnote, **H** = High, **L** = Low, **t** = Interpretive Text, @ = Reference Lab